| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
IC50: 3.83-6.84 μM (tropomyosin, in human melanoma celllines)[1].
|
|---|---|
| ln Vivo |
For TR100 and ATM-3507, the maximum dosage tolerance (MTD) is 60 mg/kg and 150 mg/kg, respectively. It is discovered that when either combination is used in place of each monotherapy, there is a notable suppression of tumor growth and an extension of animal survival. Mice treated with ATM-3507 had a median survival of 18 days, but mice treated with the combination had a median survival of over 49 days. Additionally, it is discovered that intravenous treatment of ATM-3507 twice a week also demonstrates combination efficacy. There is little effect on body weight from any one medication alone or in combination. Following the intravenous injection of 30 mg/kg of ATM-3507 in Balb/c mice (n = 3 per time point), drug levels are assessed. ATM-3507 has a mean half-life of 5.01 hours during the terminal elimination phase. In the plasma, the mean AUC0-t is 14,548 ng/h/mL. ATM-3507 has a Cmax of 5,758 ng/mL and a t1/2 of 5.01 hours. At steady state, ATM-3507's measured plasma clearance and distribution volume are 33.8 mL/min/kg and 7.23 L/kg, respectively[1].
|
| References |
| Molecular Formula |
C37H47CLFN5O2
|
|---|---|
| Molecular Weight |
648.252791643143
|
| Exact Mass |
719.293
|
| CAS # |
2438679-30-0
|
| Related CAS # |
ATM-3507;1861449-70-8
|
| PubChem CID |
139035002
|
| Appearance |
Off-white to pink solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
48
|
| Complexity |
917
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(N1C(=C(C)C2=CC(OC3C=CC=C(C(N4CCN(CCC5C=CC(F)=CC=5)CC4)=O)C=3)=CC=C12)C)CCN1CCN(C)CC1.Cl
|
| InChi Key |
IUOBZKJSPTZCIY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C37H46FN5O2.3ClH/c1-28-29(2)43(16-5-15-40-20-18-39(3)19-21-40)36-13-12-34(27-35(28)36)45-33-7-4-6-31(26-33)37(44)42-24-22-41(23-25-42)17-14-30-8-10-32(38)11-9-30;;;/h4,6-13,26-27H,5,14-25H2,1-3H3;3*1H
|
| Chemical Name |
[3-[2,3-dimethyl-1-[3-(4-methylpiperazin-1-yl)propyl]indol-5-yl]oxyphenyl]-[4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]methanone;trihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5426 mL | 7.7131 mL | 15.4261 mL | |
| 5 mM | 0.3085 mL | 1.5426 mL | 3.0852 mL | |
| 10 mM | 0.1543 mL | 0.7713 mL | 1.5426 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
